Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag331 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Mousab Al Abbas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, United States. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Basic Helix-Loop-Helix Proteins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective Management of von Hippel–Lindau (VHL) disease is challenging due to multisystem involvement and limited systemic treatment options. Belzutifan has shown promising efficacy in clinical trials; however, real-world data remain limited. We aimed to evaluate its effectiveness and safety in a real-world cohort.
Methods
We conducted a retrospective study of 59 patients with VHL disease treated with belzutifan between August 2021 and January 2026. Objective response rates (ORR) for renal cell carcinoma (RCC), central nervous system hemangioblastomas (CNS HB), and pancreatic neuroendocrine tumors (pNET) were assessed by an independent radiologist. Retinal hemangioblastoma outcomes were evaluated through ophthalmology records by chart review.
Results
Median follow-up was 29 months. ORR was 27.6%, 39.6%, and 85.7% for RCC, CNS HB, and pNET, respectively. Among 13 patients with retinal hemangioblastomas (20 eyes), 17 eyes (85%) showed improvement. At data cutoff, 47 patients (79.6%) remained on treatment, while 12 (20.3%) discontinued (7 due to adverse events, 3 to disease progression, and 2 to other reasons). The most common adverse event was anemia (86.4%). Grade ≥3 adverse events occurred in 10 patients (16.9%). The procedure rate per patient-year decreased from 0.35 in the 3 years prior to treatment to 0.08 during follow-up (Incidence Rate Ratio, 0.23; 95% CI, 0.12-0.47; P < .001)
Conclusions
Belzutifan demonstrated efficacy across VHL-associated lesions, with a favorable safety profile. Most adverse events were grade 1-2. A reduction in procedure rate was observed after treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.
- Division of Internal Medicine, University of South Alabama, Mobile, AL 36617, United States.
- Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN 55905, United States.
- Division of Radiology, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.
- Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, United States.
- Division of Urology, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.
ORCID-Profile: Mousab Al Abbas, Filippo Cingolani, Albert Jang, Irbaz Bin Riaz
Zitieren
APA
Al Abbas, M., Zarka, J., Silva, A. C., Cingolani, F., Sarfraz, M. U., Jang, A., Khan, M. A., Nahhat, F., Tan, W., Costello, B. A., Abdul-Muhsin, H., Bin Riaz, I., & Zakharia, Y. (2026). Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study. The Oncologist. https://doi.org/10.1093/oncolo/oyag331
Vancouver
Al Abbas M, Zarka J, Silva AC, Cingolani F, Sarfraz MU, Jang A, et al. Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study. The Oncologist. 2026. doi:10.1093/oncolo/oyag331
BibTeX
@article{AlAbbas2026,
author = {Al Abbas, Mousab and Zarka, Jabra and Silva, Alvin C and Cingolani, Filippo and Sarfraz, Muhammed Uzair and Jang, Albert and Khan, Muhammad Ali and Nahhat, Fouad and Tan, Winston and Costello, Brian A and Abdul-Muhsin, Haidar and Bin Riaz, Irbaz and Zakharia, Yousef},
title = {Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag331}
}
EUVIMED